Overview

Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy

Status:
Unknown status
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
- The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.
Details
Lead Sponsor:
LiNanlin,Ph.D, Chief Physician,Clinical Professor
Collaborator:
Roche Pharma AG
Treatments:
Bevacizumab